Mylan not relying on acquisitions if Perrigo bid fails: chairman

By Steven Scheer TEL AVIV (Reuters) – Mylan will likely win its bid to take over Irish-based generic drugmaker Perrigo Co, but if the bid fails the company can live without seeking an alternative acquisition, its chairman said on Wednesday. Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September with its $25 billion all-share offer. Perrigo shareholders have until Nov. 13 to accept.